Clinical Periodontology and Implant Dentistry
Total Page:16
File Type:pdf, Size:1020Kb
Index Note: page numbers in italics refer to adhesins 231, 245–6 immuneimmunmmu response 438–9 fi gures and boxes, those in bold refer to adhesion molecules 289 interinterbacterial antagonism 243–4 tables. adolescents ininvasion 248 palatal implants 1286–7 leukotoxins 214, 216, 248, 294, 438, Aae protein adhesin 217, 237 periodontal tissue breakdownown 1243 440 abortion, spontaneous 161–2, 480 plaque removal 1243 linear gingival erythema 382 abrasive agents 740–1 prosthetic oral implantant aanchorageorageMATERIAL fofor metronidazole with amoxicillin abscess orthodontics 1283–4 combination 889 periapical see also pubertyy oral cavity colonization 217 diabetes mellitus 309 adrenal functionon disorders, surgsusurgery peri-implant infection 272–3, 274 drainage 851, 852 contraindicationaindicationindication 800 periodontal disease history 276–7 see also periodontal abscess advanced fl ap procedure, root periodontal infection 213, 214, 215– absorbable collagen sponge (ACS) 1093 coverage 972, 97975–80 17, 243 abutments advancedancednced glycation eend-products periodontal lesions in diabetes 310 angulated 1198–9 (AGEs) 3103310, 311, 487 polymicrobial microbiota 226 ceramic 1233 afferentent nerve fi bers 109 prevalence in periodontal disease implant-supported restorations 1225– age 331 6, 1227, 1231 aggressivaggressive periodontitis 447–8 serotypes 216–17 Zirconia 1233 attachmattachattachment loss 144 smoking association 319 access therapy 783–820 chrochchronic periodontitis risk 424 subgingival peri-implant distal wedge procedures 794–7–7 imimplant patient 639–40 infections 639 periodontal pocket surgeryy necrotizing periodontal disease 470 suppression 883 techniques 783–94 periodontal disease 143–4 transmission 236, 237 periodontal surgery periodontal support loss 1307 virulence 243 guidelines 797–812812 see also adolescents; children aggressive periodontitis 331–2, 428–52 outcome 812–20200 Aggregatibacter actinomycetemcomitans age at onset 447–8 accessory canals 507–8, 510, 5115 145–6, 148, 149 A. actinomycetemcomitans 438–40, 441, acellular freeze-driede-dried dermal mmatrix aggressive periodontitis 438–40, 441, 448, 449–51 (ADM)M) allograftsallograf 966966–7 448, 449 alveolar bone loss 450–1 acetylsalicylicicylic acid burnbu 396 elimination 449–51 antibodies 441, 445, 449 aciclovirvirr 3793 antibiotics 450–1 associated medical conditions 446 Actinobacillusinobacillusnobacillus actinomactinactinomycetemcomitans see local delivery 893 attachment loss 429, 433, 446, 448, AggregatibaAggregatibacter microbiologic tests 890 450–1 actinomyactinomycetemcomitanstin susceptibility 886–7 bacterial etiology 437–41 Actinomycesctinomyces synergism 887 candidate genes 444–5 biofifiCOPYRIGHTED lm composition 238, 239 systemic 889 classifi cation 429–31 colonizationon 246 antibodies in aggressive clinical diagnosis 445–8 peri-implant infections 273 periodontitis 445 clinical syndromes 429–31 plaque formation 185, 186, 212 antibody response 217 crevicular fl uid prostaglandin E2 Actinomyces naeslundii antibody titers 303–4 levels 449 biofi lm on implant surfaces 268–71 association studies 438 dentition coaggregation 246 bacteriocin production 244, 247 permanent 432–3 Actinomyces viscosus 212 cardiovascular disease 157, 158 primary 432 active threshold determination 115, carotid endarterectomy 157 diabetes mellitus 446 117 clonal subset 216 diagnosis 445–9 acute necrotizing ulcerative gingivitis connective tissue invasion 440 differential diagnosis 447 (ANUG) 210, 211 diabetes mellitus 245 drug-induced granulocytopenia 446 etiology 212 elimination by extraction of all environmental factors 445, 446 microbial invasion 294 teeth 274 epidemiology 431–3 smokers 317 growth inhibition factors 243, 247 etiology 437–41 spirochetes 221 HIV infection 244 familial aggregation 447 i2 Index aggressive periodontitis (continued) orthodontic loading 363–5 horizontal 1091–2 forms 428 osteoclast activity 41 regeneration 1084 furcation involvement 657–67 osteoporosis 89–91 soft tissue grafts 1089 generalized 428, 429, 430, 431, 440, patient examination 583 vertical 1092 441, 447 radiographic analysis 576, 583 extraction sockets 1089–90 genetic diagnosis 449 regrowth 542 healed following tooth loss 1063 genetic factors 441–5 remodeling 42 preservation 1088–9 heritability 331–2 renewal 40, 41 alveolar ridge, edentulous 50–67 HIV infection 446 repair 94–5 atrophy following tooth loss 1060–1 host defense evaluation 448–9 resorption 41, 42, 66, 67 augmentation 1011–17, 1018–19, 1020, host response to bacterial periodontitis 440 1021–3 pathogens 440–1 pulpal infl ammatory response 506, bone gain 53 host susceptibility 441–5 508 bone loss 53 hypophosphatasia 446 turnover with orthodontic bone marrow 67 implants 661 loading 364 bundle bone 63, 64 planning 680–2 alveolar bone proper 3, 4, 5, 36, 38, 42 classifi cation of remaining bonene 535 inheritance 442–5 lamellar bone 37 defect correction 1010–11 leukemia 446 periodontal ligament 28 deformed 1008–17, 1018–19–19, 1020,102 leukocyte adhesion defi ciency 446 fi bers 30, 32, 33, 42 1021–3 local infl ammatory responses 441 resorption 63 extra-alveolar processesessess 62–6 localized 140–1, 213, 215–17, 428, 429, Sharpey’s fi bers 38, 42 free graft proceduresuresres 1013–17,1013–1 1018–10 430–1, 437–41, 447 tooth attachment 37 19, 1020, 1021–3021–3 microbiologic diagnosis 445–8 tooth extraction 55 gingivoplastyty soft tissue microbiologic testing 451–2 tooth socket healing 63, 64, 65 sculptingpting 1020, 1021–31021– orthodontic therapy 662, 665 alveolar crest 28 implantnt placementplacemen 1055–6,105 1057, palmo-plantar keratitis 446 distance to cemento-enamel 1058–61, 106262 pathogenesis 441–5 junction 434–7 interpositionalterpositional graftgragr procedures 1014, pathogenic fl ora elimination/ fi bers 28 10155, 1016 suppression 449–52 outline 657 combined withw onlay grafts 1020 periodontal probing 437 preparation for implant intra-alveolarintra-alveoalve processes 54–5, 56, 57, periodontium rate of destruction placement 1072 58–958–TERIAL, 60, 61, 62 447 recontouring 832 lamellarlamel bone 67 permanent dentition 432–3 width determination 1068–9 onlayonl graft procedures 1015–17, polymorphonuclear leukocytes 441 alveolar crestal height (ACH) 900 1018–19, 1020, 1021–3 P. gingivalis 440, 441, 448 alveolar mucosa 5, 7–8, 15 combined with interpositional primary dentition 432 necrotizing periodontal diseadisease 462,MATE grafts 1020 prosthetic treatment 661 463, 464 osseointegration 99 restorative therapy 662, 665 transplanted 24, 25–75–7–7 pedicle grafts 1011–13 restorative treatment 661 alveolar nerve, inferiorerior 48 pontic contours 1020, 1021–3 screening 433–7 tooth extractionon 120 pouch graft procedures 1013–14 sibling monitoring 448 alveolar plexus,us, superior 48 remaining bone 52–3 smoking 432–3, 445, 446 alveolar processrocess 3, 27, 28,,3 34–53 soft tissue collapse surgery 661, 663 adaptationation after tooth extraction prevention 1009–10 therapeutic intervention 449–52 1059059 soft tissue grafts 1010–11 treatment 657–67 boneone 86–95 surgical procedures for agranulocytosis, surgery cancellous 11063 augmentation 1011–17, 1018–19, contraindication 800 lamellaramel 337, 54 1020, 1021–3 AIDS see HIV infection loss 86 topography 66–7 alcohol abuse, implant patient 645 sponspongypo 54 amalgam tattoo 398 alcohol consumption, necrotizing corticcorticortical plates 53, 54 ameloblasts 16 periodontal disease 470 CT 1286 amine alcohols, plaque control 746–7 alexidine, plaque control 744 edentulous alveolar ridge 50, 51, 52–3 amine fl uoride 746 allele frequencies 330 formation 37 amino acids, sulfur-containing 1326 allergic reactions 393, 6900 mineralization 37 amoeba 209 oral mucosa 392–4 resorption rate 1089 amoxicillin 450, 451, 886 periodontium 8499 tooth extraction 54–5, 56, 57, 58–9, 60, metronidazole combination 889 alloplastic grafts 552–3552– 61, 62–6 peri-implant lesions 878 alveolar bone 3, 27–8,7–8, 34–42,34– 8686–95 topography 53–4, 55 amphotericin B 752 blood vesselssels 45, 46 alveolar pyorrhea, trauma from amyloglucosidase, plaque control 744 dehiscencencee 36 occlusion association 349–50 analgesia 691 gingivalngival recession 961, 1267, 1269 alveolar ridge anchorage depositionposition 42 augmentation 1011–17, 1018–19, 1020, orthodontic destructionstruction 5105 1021–3 absolute 1280–90, 1291 fenestrationnestrationestration 336 clinical concepts 1088–92 implants as temporary formationationCOPYRIGHTED 3 39, 86 dehiscence defects 1090–1 devices 1284–8, 1289, 1290, healing 888–9 differentiation factors 1093 1291 height 657 extraction sockets 1089–90 indications for implants 1283, loss 86, 92–3 growth factors 1093 1284 aggressive periodontitis 450–1 horizontal defects 1091–2 length-reduced devices 1285 children 140–1 horizontal tooth movement 1264–5, skeletal systems 1281 diabetes mellitus 488 1267, 1268 temporary devices 1282 osseous surgery 795 long-term results 1087–8 anchoring fi bers 12, 13 P. gingivalis 219 materials 1085–7 androgens 408 radiographic assessment 131 procedures 1083–94 anemia, surgery contraindication 800 risk assessment 1307 vertical defects 1092 angina pectoris, surgery smokers 318 vertical tooth movement 1263–4, contraindication 799 trauma from occlusion 360 1265, 1266 angiogenesis 60 membrane barriers 94, 95 defects angular bone necrosis 462 correction 1010–11 defects 351, 360 neurovascularization 109–10 dehiscence 1090–1 destruction 358, 359 Volume 1, pp. 1–570; Volume 2, pp. 571–1340 Index i3 ankylosis 547 antiplaque agents 734, 740, 742–60 cardiovascular disease 157, 158 external infl ammatory root